Etablierung von zirkulierenden DNA-Fragmenten als Biomarker für die klinische Progression einer Herzinsuffizienz mit erhaltener Ejektionsfraktion
Establishing predictive modelling of heart failure with preserved ejection fraction progression
von Marleen Awe
Datum der mündl. Prüfung:2020-02-25
Erschienen:2020-02-21
Betreuer:Prof. Dr. Elisabeth Zeisberg
Gutachter:Prof. Dr. Thomas Meyer
Gutachter:Prof. Dr. Martin Oppermann
Dateien
Name:Doktorarbeit_Marleen_Awe_v33_ABGEGEBEN_Sub.pdf
Size:1.11Mb
Format:PDF
Zusammenfassung
Englisch
Chronic heart disease is associated with abberant CpG promoter methylation, mechanistically involved cardiac fibrogenesis. Aberant CpG promoter methylation is equally reflected in corresponding blood samples („liquid biopsy“). Established HFpEF markers poorly correlate with circulating methylated RASAL1, B9D1 and ATP2A2. Established HFpEF markers BNP/NT-proBNP insufficiently identify patients at risk for HFpEF death. Circulating methylated RASAL1, B9D1 and ATP2A2 most effectively identify patients at risk for HFpEF progression.
Keywords: liquid biopsy; HFpEF; heart failure with preserved ejection fraction; methylated DNA; biomarker; RASAL1; ATP2A2; B9D1